Margaret Kloster

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa

Félix Ratjen, Lisa Saiman, Nicole Mayer-Hamblett et al. · CHEST Journal · 2012 · 121 citations · Full text

Veterinary Medicine, Microbiology, Pharmacology +13

Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life

Daniel H. Leung, Sonya L. Heltshe, Drucy Borowitz et al. · JAMA Pediatrics · 2017 · 107 citations · Full text

Medicine, Nutrition, Pediatrics +17

Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Nicole Mayer-Hamblett, George Retsch‐Bogart, Margaret Kloster et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 98 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Multicenter Evaluation of Infant Lung Function Tests as Cystic Fibrosis Clinical Trial Endpoints

Stephanie D. Davis, Margaret Rosenfeld, Gwendolyn S. Kerby et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 95 citations · Full text

Medicine, Clinical Sciences, Pediatrics +17